Which characteristic best distinguishes live attenuated vaccines (LAV) from inactivated vaccines in terms of immune response generation and contraindication in immunocompromised hosts?

Question

Accepted Answer

B. LAVs produce stronger mucosal IgA response and cell-mediated immunity but carry risk of vaccine-strain disease in immunocompromised patients; inactivated vaccines are safer but generate weaker mucosal immunity. ## Live Attenuated vs Inactivated Vaccines: Immune Response & Safety

### Comparative Immunology

| Feature | Live Attenuated Vaccines (LAV) | Inactivated Vaccines |
| --- | --- | --- |
| **Immune response type** | Cellular (Th1, CTL) + Humoral (IgG, IgA) | Primarily humoral (IgG, IgM) |
| **Mucosal immunity (IgA)** | Strong (especially oral LAVs) | Weak to absent |
| **Duration of immunity** | Often lifelong (1–2 doses) | Requires periodic boosters |
| **Contraindication in immunocompromised** | YES — risk of vaccine-strain disease | NO — safe |
| **Pregnancy safety** | Contraindicated (teratogenic risk) | Safe |
| **Replication in host** | Yes (attenuated) | No (killed antigen) |

### Why LAVs Are Contraindicated in Immunocompromised Hosts

1. **Vaccine-strain reversion**: Live attenuated organisms can revert to virulence or cause disseminated infection in patients with CD4 <200 cells/μL or severe neutropenia.
2. **Examples of contraindication**: MMR, varicella, rotavirus, and oral polio vaccine (OPV) are contraindicated in HIV/AIDS, severe combined immunodeficiency (SCID), and post-transplant patients.
3. **Inactivated alternatives**: IPV (instead of OPV), inactivated influenza, and hepatitis A vaccines are safe options for immunocompromised patients.

### Mucosal Immunity Advantage of LAVs

**Key Point:** LAVs (especially oral vaccines like OPV and rotavirus) induce robust secretory IgA at mucosal surfaces, providing local protection. Inactivated vaccines (parenteral) generate systemic IgG but weak mucosal IgA.

**Clinical Pearl:** This is why oral polio vaccine was historically preferred in polio eradication campaigns — superior mucosal immunity interrupted fecal-oral transmission. However, inactivated polio vaccine (IPV) is now preferred in routine programs due to safety in immunocompromised populations.

**High-Yield:** The trade-off is clear: LAVs offer superior breadth of immunity (cellular + mucosal) but carry safety risks in immunocompromised hosts; inactivated vaccines are universally safe but require boosters and generate weaker mucosal responses.

**Mnemonic:** **LAV-RISK** = Live Attenuated Vaccines — Replication In host, Strong cellular immunity, Contraindicated in immunocompromised, Kinder mucosal response.

Answer

A. LAVs induce both cellular and mucosal immunity but are contraindicated in immunocompromised patients; inactivated vaccines induce only humoral immunity and are safe in immunocompromised hosts

Answer

C. LAVs generate only IgM antibodies, while inactivated vaccines generate IgG and IgM; both are safe in HIV-positive individuals

Answer

D. Inactivated vaccines require multiple booster doses to maintain immunity, whereas LAVs provide lifelong immunity after a single dose in all populations

Which characteristic best distinguishes live attenuated vaccines (LAV) from inactivated vaccines in terms of immune response generation and contraindication in immunocompromised hosts?

Explanation

Practice similar questions